Emmanson Emmanson Godswill¹*, Eze Constance Nonye², Amagwula Ikechukwu Otuosorochi³, Anthonia Bolanle Ojomo⁴, Toluwalope Y Oni⁵, Abdwahab Abdsalam Babatunde⁶, Uchechukwu Gift Chinenye⁷ and Ochai Onyiba Blessing⁸

¹Department of Human Anatomy, Cross River University of Technology, Nigeria
²Department of Public Health, Federal University of Technology, Owerri
³Department of Community Health, Glasgow Caledonian University
⁴Department of Pharmacy, Universite De Parakou
⁵Department of Biochemistry, Federal University of Technology, Akure
⁶Department of Biochemistry, Olabisi Onabanjo University
⁷Department of Pharmaceutical Sciences, University of Nigeria, Nsukka
⁸Department of Medical laboratory Science, University of Jos

*Corresponding Author: Emmanson Emmanson Godswill, Department of Human Anatomy, Cross River University of Technology, Nigeria.

Received: February 27, 2024; Published: March 04, 2024

Abstract

Neurodegenerative diseases, such as Alzheimer's disease (AD), Parkinson's disease (PD), and Huntington's disease (HD), are disorders that affect the structure and function of neurons in the central nervous system, leading to progressive loss of cognitive and motor abilities. Understanding the complex pathophysiology underlying these disorders is crucial for the development of effective therapeutic interventions. In this literature review, we explored recent advancements in elucidating the pathogenesis of neurodegenerative diseases and identify emerging therapeutic targets based on a selection of key review articles, original research papers, and clinical trials. We focused on the role of amyloid-beta (Aβ) and calcium dysregulation in AD, alpha-synuclein (α-syn) and deep brain stimulation in PD, and mutant huntingtin and gene silencing in HD. We also discussed the challenges and opportunities in translating promising preclinical findings into effective treatments, and highlighted the need for a comprehensive understanding of the molecular and cellular mechanisms underlying neurodegeneration, as well as the identification of novel biomarkers and therapeutic targets.

Keywords: Neurodegenerative Diseases; Alzheimer's Disease; Parkinson's Disease; Huntington's Disease; Protein Aggregation; Neuroinflammation; Calcium Dysregulation; Therapeutic Targets; Amyloid-Beta; Alpha-Synuclein; Mutant Huntingtin; Clinical Trials; Biomarkers; Genetics; Environmental Factors; Neuroanatomy; Neurochemistry

References

1. Alzheimer's Disease Genetics Consortium. “The Alzheimer's Disease Genetics Consortium: a collaborative effort to identify Alzheimer's disease risk genes”. Neuron 4 (2013): 545-548.
2. Bezprozvanny I and Mattson MP. “Neuronal calcium mishandling and the pathogenesis of Alzheimer's disease”. Trends in Neurosciences9 (2008): 454-463.
3. Braak H and Del Tredici K. “The pathological process underlying Alzheimer's disease in individuals under thirty”. Acta Neuropathologica2 (2011): 171-181.
4. Chartier-Harlin MC., et al. “Alpha-synuclein locus duplication as a cause of familial Parkinson's disease”. The Lancet8760 (1991): 1316-1317.
5. DiFiglia M., et al. “Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain”. Science 5334 (1997): 1990-1993.
6. Doody, RS., et al. “A phase 3 trial of semagacestat for treatment of Alzheimer's disease”. New England Journal of Medicine4 (2014): 341-350.
7. Hardy J and Selkoe DJ. “The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics”. Science5580 (2002): 353-356.
8. Heneka MT., et al. “Neuroinflammation in Alzheimer's disease”. The Lancet Neurology4 (2015): 388-405.
9. Jucker M and Walker LC. “Self-propagation of pathogenic protein aggregates in neurodegenerative diseases”. Nature 7465 (2013): 45-51.
10. Lang AE and Gill S. “Parkinson's disease: first of two parts”. New England Journal of Medicine 3 (2017): 2565-2576.
11. Lang AE and Lozano AM. “Parkinson's disease”. New England Journal of Medicine15 (1998): 1044-1053.
12. Orr HT and Zoghbi HY. “Trinucleotide repeat disorders”. Annual Review of Neuroscience 30 (2007): 575-621.
13. Ross CA and Poirier MA. “Protein aggregation and neurodegenerative disease”. Nature Medicine 10 (2004): S10-S17.
14. Selkoe DJ and Hardy J. “The amyloid hypothesis of Alzheimer's disease at 25 years”. EMBO Molecular Medicine6 (2016): 595-608.
15. Spillantini MG., et al. “α-Synuclein in Lewy bodies”. Nature 6645 (1997): 839-840.
16. Tabrizi SJ., et al. “Targeting Huntingtin Expression in Patients with Huntington's Disease”. New England Journal of Medicine24 (2019): 2307-2316.
17. Vargas LM and Johnson JA. “Current and potential treatments for Alzheimer's disease”. Current Neuropharmacology 4 (2010): 574-584.

Citation

Citation: Emmanson Emmanson Godswill., et al. “A Study on Pathophysiology and Emerging Therapeutic Targets of Neurodegenerative Diseases".Acta Scientific Anatomy 3.3 (2024): 03-11.

Copyright

Copyright: © 2024 Emmanson Emmanson Godswill., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.